173 related articles for article (PubMed ID: 32713209)
1. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E; Fotiou D; Theodorakakou F; Dialoupi I; Migkou M; Roussou M; Karatrasoglou EA; Tselegkidi MI; Ntalianis A; Kanellias N; Eleutherakis-Papaiakovou E; Ntanasis-Stathopoulos I; Gakiopoulou C; Papanikolaou A; Papathoma A; Spyropoulou-Vlachou M; Psimenou E; Stamatelopoulos K; Gavriatopoulou M; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):3-11. PubMed ID: 32713209
[TBL] [Abstract][Full Text] [Related]
2. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
[TBL] [Abstract][Full Text] [Related]
3. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
4. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
[TBL] [Abstract][Full Text] [Related]
5. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
[TBL] [Abstract][Full Text] [Related]
6. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.
Sarosiek S; Zheng L; Sloan JM; Quillen K; Brauneis D; Sanchorawala V
Blood Cancer J; 2020 Sep; 10(8):88. PubMed ID: 32873776
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
8. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
11. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Holzhey T; Pönisch W; Wang SY; Holzvogt M; Holzvogt B; Andrea M; Zehrfeld T; Hammerschmidt D; Hoffmann FA; Becker C; Schwarzer A; Schwarz M; Schönfelder-Fricke U; Edelmann T; Braunert L; Franke GN; Jentzsch M; Schwind S; Bill M; Grimm J; Remane Y; Platzbecker U; Scholz M
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2349-2359. PubMed ID: 33433659
[TBL] [Abstract][Full Text] [Related]
13. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
14. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
[TBL] [Abstract][Full Text] [Related]
15. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
16. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
17. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).
Tandon N; Sidana S; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Buadi FK; Fonder AL; Hayman SR; Hwa YL; Hobbs MA; Kapoor P; Gonsalves WI; Leung N; Go RS; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Kumar SK
Am J Hematol; 2018 Jan; 93(1):17-22. PubMed ID: 28960427
[TBL] [Abstract][Full Text] [Related]
18. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
19. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
